These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 28776468)

  • 21. Pharmacogenetic potential biomarkers for carbamazepine adverse drug reactions and clinical response.
    Jaramillo NM; Galindo IF; Vázquez AO; Cook HJ; LLerena A; López ML
    Drug Metabol Drug Interact; 2014; 29(2):67-79. PubMed ID: 24406279
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.
    Yamamoto PA; Conchon Costa AC; Lauretti GR; de Moraes NV
    Pharmacogenomics; 2019 Aug; 20(13):971-982. PubMed ID: 31486733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genotyping as a tool to predict adverse drug reactions.
    Güzey C; Spigset O
    Curr Top Med Chem; 2004; 4(13):1411-21. PubMed ID: 15379654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic literacy series: clinical application of pharmacogenetics for adverse reactions to antiepileptic drugs.
    Zhang Z; Wu Y; Tan NC; Jiang Y
    Epileptic Disord; 2019 Aug; 21(4):330-336. PubMed ID: 31403464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing.
    Lauschke VM; Ingelman-Sundberg M
    Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects.
    Lynch T; Price A
    Am Fam Physician; 2007 Aug; 76(3):391-6. PubMed ID: 17708140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fixed-dose combination products and unintended drug interactions: urgent need for pharmacogenetic evaluation.
    Duconge J; Ruaño G
    Pharmacogenomics; 2015; 16(15):1685-8. PubMed ID: 26431456
    [No Abstract]   [Full Text] [Related]  

  • 28. [Individualized pharmacotherapy based on cytochrome P-450 (CYP) genotyping].
    Johansen PW; Bergan S; Rootwelt H; Kvittingen EA; Rugstad HE
    Tidsskr Nor Laegeforen; 2002 Nov; 122(29):2781-3. PubMed ID: 12523145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics in geriatric medicine: challenges and opportunities for clinical practice.
    Pilotto A; Panza F; Seripa D
    Curr Drug Metab; 2011 Sep; 12(7):621-34. PubMed ID: 21495974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Perception of the usefulness of drug/gene pairs and barriers for pharmacogenomics in Latin America.
    Quinones LA; Lavanderos MA; Cayun JP; Garcia-Martin E; Agundez JA; Caceres DD; Roco AM; Morales JE; Herrera L; Encina G; Isaza CA; Redal MA; Larovere L; Soria NW; Eslava-Schmalbach J; Castaneda-Hernandez G; Lopez-Cortes A; Magno LA; Lopez M; Chiurillo MA; Rodeiro I; Castro de Guerra D; Teran E; Estevez-Carrizo F; Lares-Assef I
    Curr Drug Metab; 2014 Feb; 15(2):202-8. PubMed ID: 24524664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: The prevalence and clinical relevance of cytochrome P450 polymorphisms.
    Wijnen PA; Op den Buijsch RA; Drent M; Kuijpers PM; Neef C; Bast A; Bekers O; Koek GH
    Aliment Pharmacol Ther; 2007 Dec; 26 Suppl 2():211-9. PubMed ID: 18081664
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population.
    Halling J; Petersen MS; Damkier P; Nielsen F; Grandjean P; Weihe P; Lundgren S; Lundblad MS; Brøsen K
    Eur J Clin Pharmacol; 2005 Aug; 61(7):491-7. PubMed ID: 16025294
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacogenetics of second-generation antipsychotics.
    Brennan MD
    Pharmacogenomics; 2014 Apr; 15(6):869-84. PubMed ID: 24897292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of pharmacogenetics in clinical practice: problems and solutions.
    Baskys A
    J Neural Transm (Vienna); 2019 Jan; 126(1):109-113. PubMed ID: 29922908
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacogenetics of chemotherapy-induced nausea and vomiting.
    Sugino S; Janicki PK
    Pharmacogenomics; 2015 Jan; 16(2):149-60. PubMed ID: 25616101
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk.
    Bozina N; Bradamante V; Lovrić M
    Arh Hig Rada Toksikol; 2009 Jun; 60(2):217-42. PubMed ID: 19581216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction.
    Rufini S; Ciccacci C; Politi C; Giardina E; Novelli G; Borgiani P
    Pharmacogenomics; 2015 Nov; 16(17):1989-2002. PubMed ID: 26555663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of pharmacogenomics and therapeutic drug monitoring for opioid pain management.
    Jannetto PJ; Bratanow NC
    Pharmacogenomics; 2009 Jul; 10(7):1157-67. PubMed ID: 19604091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.
    Wilffert B; Swen J; Mulder H; Touw D; Maitland-Van der Zee AH; Deneer V;
    Int J Clin Pharm; 2011 Feb; 33(1):3-9. PubMed ID: 21365387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.
    Negrini S; Becquemont L
    Pharmacogenomics; 2017 Oct; 18(15):1441-1457. PubMed ID: 29017379
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.